Why the study?
The study aimed to evaluate 10-year cardiovascular risk assessment in the common carotid artery versus carotid bulb using the AECRS2.0 calculator and compare AECRS2.0 to conventional risk calculators.
Does risk assessment in the carotid bulb using AECRS2.0 improve 10-year CVD/stroke risk prediction compared to the common carotid artery or conventional calculators in patients with T2DM, CKD, or hypertension?
Does risk assessment in the carotid bulb using AECRS2.0 improve 10-year CVD/stroke risk prediction compared to the common carotid artery or conventional calculators in patients with T2DM, CKD, or hypertension?
Ultrasound-based risk assessment using the carotid bulb may offer superior 10-year cardiovascular risk prediction compared to the common carotid artery and conventional risk calculators in high-risk patients.
May support segment-specific carotid risk scoring; leaves open need for prospective validation vs conventional calculators.
The objectives of this study are to (1) examine the “10-year cardiovascular risk” in the common carotid artery (CCA) versus carotid bulb using an integrated calculator called “AtheroEdge Composite Risk Score 2.0” (AECRS2.0) and (2) evaluate the performance of AECRS2.0 against “conventional cardiovascular risk calculators.” These objectives are met by measuring (1) image-based phenotypes and AECRS2.0 score computation and (2) performance evaluation of AECRS2.0 against 12 conventional cardiovascular risk calculators. The Asian–Indian cohort (n = 379) with type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or hypertension were retrospectively analyzed by acquiring the 1516 carotid ultrasound scans (mean age: 55 ± 10.1 years, 67% males, ∼92% with T2DM, ∼83% with CKD [stage 1-5], and 87.5% with hypertension [stage 1-2]). The carotid bulb showed a higher 10-year cardiovascular risk compared to the CCA by 18% ( P < .0001). Patients with T2DM and/or CKD also followed a similar trend. The carotid bulb demonstrated a superior risk assessment compared to CCA in patients with T2DM and/or CKD by showing: (1) ∼13% better than CCA (0.93 vs 0.82, P = .0001) and (2) ∼29% better compared with 12 types of risk conventional calculators (0.93 vs 0.72, P = .06).
No takes yet. Share an insight, caveat, or question.
Viswanathan et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: